{"id":237461,"date":"2026-09-09T12:29:29","date_gmt":"2026-09-09T06:59:29","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=237461"},"modified":"2026-09-09T12:29:29","modified_gmt":"2026-09-09T06:59:29","slug":"is-best-agrolife-a-good-buy-after-q1-fy27-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/is-best-agrolife-a-good-buy-after-q1-fy27-results\/","title":{"rendered":"Is Best Agrolife a Good Buy After Its Q1 FY27 Results?"},"content":{"rendered":"

Best Agrolife share price around Rs 19. 43.4% below 52-week high of Rs 34. Q1 FY27 revenue Rs 398 crore, up 3.3% YoY. PAT Rs 41 crore, up 104.1%. PE 24x.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Best Agrolife’s Q1 FY27 results were strong, with revenue at Rs 398 crore and PAT climbing 104% to Rs 41 crore. The stock trades at a PE of 24x against an industry average near 26x, which leaves room for a re-rating if this growth continues. The Best Agrolife share price near Rs 19 reflects that optimism, so investors weighing whether Best Agrolife is a good buy today should focus on whether this pace of growth can be sustained rather than just this quarter’s print.<\/p>\n<\/p><\/div>\n

The Best Agrolife share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Best Agrolife is formerly Sahyog Multibase, a leading Indian agrochemicals manufacturer, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.<\/p>\n

Revenue for the quarter came in at Rs 398 crore, up 3.3% year on year, while profit after tax came in at Rs 41 crore, up 104.1% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Best Agrolife share price from here.<\/p>\n

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Best Agrolife share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n